Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
16 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/genprex-receives-safety-review-committee-approval-to-advance-to-phase-2-portion-of-acclaim-3-clinical-trial-of-reqorsa-gene-therapy-in-combination-with-tecentriq-in-extensive-stage-small-cell-lung-cancer-302332325.html
05 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-data-on-reqorsa-gene-therapy-at-the-society-for-immunotherapy-of-cancer-2024-annual-meeting-302296343.html
15 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/genprex-receives-safety-review-committee-approval-to-advance-to-highest-dose-group-in-phase-1-portion-of-acclaim-3-clinical-trial-of-reqorsa-gene-therapy-in-combination-with-tecentriq-in-extensive-stage-small-cell-lung-cancer-302276249.html
10 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-the-2024-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-302272661.html
04 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/genprex-announces-plans-to-launch-separate-company-to-focus-on-the-development-of-gene-therapy-to-treat-type-1-and-type-2-diabetes-302237871.html
15 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/vimgreen-completes-enrollment-of-its-phase-2-clinical-trial-evaluating-vg081821ac-for-the-treatment-of-parkinsons-disease-302223602.html
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) is being investigated in combination with Tecentriq for extensive-stage small cell lung cancer.
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Brand Name: Reqorsa
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2024
Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Genprex Advances Reqorsa® Gene Therapy in Acclaim-3 for Lung Cancer
Details : Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) is being investigated in combination with Tecentriq for extensive-stage small cell lung cancer.
Brand Name : Reqorsa
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 15, 2024
Details:
GPX-002 is a gene therapy drug candidate, designed to work by transforming alpha cells in the pancreas into functional beta-like cells for the treatment of Type 1/2 diabetes.
Lead Product(s): GPX-002
Therapeutic Area: Endocrinology Brand Name: GPX-002
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2024
Lead Product(s) : GPX-002
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Genprex Plans New Company For Gene Therapy Development in Diabetes Treatment
Details : GPX-002 is a gene therapy drug candidate, designed to work by transforming alpha cells in the pancreas into functional beta-like cells for the treatment of Type 1/2 diabetes.
Brand Name : GPX-002
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 04, 2024
Details:
Reqorsa (quaratusugene ozeplasmid) is a Immunogene Therapy which is being investigated in combination with Tecentriq in extensive-stage small cell lung cancer.
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Brand Name: Reqorsa
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2024
Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Genprex Provides Positive Updates from Acclaim-1 and Acclaim-3 Lung Cancer Trials
Details : Reqorsa (quaratusugene ozeplasmid) is a Immunogene Therapy which is being investigated in combination with Tecentriq in extensive-stage small cell lung cancer.
Brand Name : Reqorsa
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 14, 2024
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq in extensive-stage small cell lung cancer.
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Brand Name: Reqorsa
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2024
Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Genprex Doses First Patient in Acclaim-3 Study of Reqorsa® for Lung Cancer
Details : Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq in extensive-stage small cell lung cancer.
Brand Name : Reqorsa
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 14, 2024
Details:
NPRL2 gene therapy induces effective anti-tumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.
Lead Product(s): NPRL2 Gene Therapy
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Lead Product(s) : NPRL2 Gene Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Genprex Publishes Positive Preclinical Data with NPRL2 Gene Therapy Using Oncoprex® System
Details : NPRL2 gene therapy induces effective anti-tumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 02, 2024
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq for the treatment of small cell lung cancer.
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Brand Name: Reqorsa
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Genprex Inc. Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
Details : Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq for the treatment of small cell lung cancer.
Brand Name : Reqorsa
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 21, 2023
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq in extensive-stage small cell lung cancer.
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Brand Name: Reqorsa
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatme...
Details : Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq in extensive-stage small cell lung cancer.
Brand Name : Reqorsa
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 10, 2023
Details:
Under the agreement, Genprex gains a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy, GPX-002, for both Type 1 and Type 2 diabetes.
Lead Product(s): GPX-002
Therapeutic Area: Endocrinology Brand Name: GPX-002
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Recipient: The University of Pittsburgh School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 18, 2023
Lead Product(s) : GPX-002
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : The University of Pittsburgh School of Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Genprex gains a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy, GPX-002, for both Type 1 and Type 2 di...
Brand Name : GPX-002
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 18, 2023
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tagrisso in advanced non-small cell lung cancer.
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Brand Name: Reqorsa
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tagrisso in advanced non-small cell lung cancer.
Brand Name : Reqorsa
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 11, 2023
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX Nanoparticle Delivery System and Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area: Oncology Brand Name: Reqorsa
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX Nanoparticle Delivery System and Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Brand Name : Reqorsa
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 28, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?